Biosimilar Contract Manufacturing Market (2026 - 2035)

Biosimilar Contract Manufacturing Market Research Report Information By Product (Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins), By Production Technology (Mammalian and Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Forecast Period
2026-2035
CAGR
14.9%
2025 Market Size
USD 12.82 Billion
2035 Market Size
USD 51.42 Billion
Pharmaceutical ● Updated August 25, 2026 Report ID: MRFR/Pharma/10382-HCR | Pages: 128 | Author: Rahul Gotadki, Nidhi Mandole

Biosimilar Contract Manufacturing Market Summary

The Biosimilar Contract Manufacturing Market reached USD 12.82 billion in 2025 and opens the forecast window at USD 14.73 billion in 2026, climbing to USD 51.42 billion by 2035 at a 14.9% CAGR. Two catalysts anchor that trajectory. The first is the patent cliff: roughly USD 180 billion in annual biologic sales lose exclusivity between 2026 and 2032, and most sponsors chasing those molecules do not own commercial-scale bioreactor capacity [1][3]. The second is payer pressure — the US Inflation Reduction Act's negotiation list and Europe's tender-driven procurement have compressed reference-product pricing to the point where in-house plants rarely clear their cost of capital [2].

Manufacturing is remaking itself. Stainless-steel fed-batch lines of 12,000 to 20,000 liters are being replaced by single-use, intensified perfusion lines with 2,000-liter bioreactors that operate at four to six times the volumetric productivity, reducing capital intensity per gram by almost 40%. Samsung Biologics, Lonza and WuXi Biologics have together committed more than USD 12 billion to new capacity since 2023, much of it intended for biosimilar medication manufacture rather than innovative biologics [4][5][6].

 

North America accounts for 41.5% of global revenue, spurred by FDA interchangeability channels and a solid contract-development basis. Asia-Pacific will lead the growth at 17.6% CAGR through 2035, driven by capacity build-outs in Korea and China. Europe follows with a 27.0% share, where EMA’s 2024 tailored-comparability guidance is compressing development schedules. The next ten years are going to reward manufacturers who can show analytical comparability faster than they can pour concrete.

 

Key Report Takeaways

• By Technology

  • Mammalian expression systems command 74.5% of the Biosimilar Contract Manufacturing Market, reflecting antibody dominance in the off-patent pipeline.
  • Microbial platforms generate USD 3.27 billion, concentrated in insulins, filgrastim and teriparatide programs.

• By Sector

  • Oncology applications hold 42.8% revenue share, led by trastuzumab, bevacizumab and rituximab follow-ons.
  • Infectious disease indications post the strongest application CAGR at 16.4%
  • Upstream processing services account for 35.2% of outsourced spend

• By Geography

  • North America contributes USD 5.32 billion to the Biosimilar Contract Manufacturing Market in 2025
  • Asia-Pacific advances at a 17.6% CAGR, the fastest of any region
  • South America represents 5.2% of global revenue, anchored by Brazilian public procurement

 

Market Size and Forecast (2021–2035)

Below estimates triangulate audited CDMO segment revenues, published capacity utilization rates, regulatory file volumes at FDA and EMA, and interview input from 42 sponsor-side procurement leads. Historical numbers are reconciled to firm annual reports. For projection years, a capacity-constrained demand model is used for the Biosimilar Contract Manufacturing Market.

Biosimilar Contract Manufacturing Market Size and Forecast
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Driver Impact Analysis

Driver ~% Impact on CAGR Geographic Relevance Impact Timeline
Biologic patent cliff 2026–2032 4.1 Global Short-term (≤2 yr)
Payer cost-containment mandates 2.8 US, EU, Japan Short-term (≤2 yr)
Capital avoidance by mid-cap sponsors 2.4 Global Medium-term (2–4 yr)
Single-use and perfusion intensification 2.2 NA, EU, Korea Medium-term (2–4 yr)
Regulatory streamlining of comparability 1.9 EU, US Medium-term (2–4 yr)
Emerging-market access programs 1.3 APAC, LATAM, MEA Long-term (≥4 yr)
Onshoring and supply-chain resilience policy 0.9 US, EU, India Long-term (≥4 yr)

 

The Patent Cliff Is the Demand Engine

Payer Economics Force Cost Discipline

Medicare's negotiated maximum fair prices took effect in January 2026 for the first ten selected drugs, with seven biologics in the second tranche [2]. European tender systems already clear biosimilar insulins and anti-TNFs at 65–80% discounts to originator list price. At those realisations, a sponsor needs cost of goods below USD 40 per gram of drug substance — achievable at a specialist contract site running 6 g/L titres, rarely achievable in a captive plant at 40% utilisation. Procurement teams have responded by shifting roughly 71% of new biosimilar programs to external manufacture [8].

Process Intensification Rewrites Unit Economics

Perfusion and high-density fed-batch processes have lifted typical monoclonal antibody titres from 2–3 g/L to 6–9 g/L over eight years [5]. Lonza's Visp facility and Samsung Biologics Plant 5 both deploy intensified trains that deliver the output of a legacy 15,000-litre stainless line from a 4,000-litre single-use suite. Capital per annual kilogram falls by 38–45%, and changeover between programs drops from 12 weeks to under four. For contract manufacturers, that means more programs per suite per year — the single most powerful margin lever available.

Regulatory Convergence Shortens Development

EMA's 2024 reflection paper on tailored clinical development signalled that comparative efficacy trials may be waived where analytical and PK similarity is robust [9]. FDA followed with draft guidance in 2025 easing switching-study requirements for interchangeability. Removing a Phase III comparative trial saves a sponsor USD 60–100 million and 24 months — but raises the analytical burden, which flows straight to contract laboratories.

 

Restraints Impact Analysis

The weightings below represent estimated drag on growth and are directional. They reflect analyst judgement on how severely each constraint suppresses realised demand within the Biosimilar Contract Manufacturing Market rather than a subtractive calculation.

Restraint ~% Drag on CAGR Geographic Relevance Impact Timeline
Capacity overbuild and price erosion. 2.3 Global Medium-term (2–4 yr)
Tech transfer complexity and failure risk 1.7 Global Short-term (≤2 yr)
Skilled bioprocess talent shortage 1.4 US, EU, Korea Medium-term (2–4 yr)
Geopolitical restrictions on cross-border supply 1.1 US–China corridor Short-term (≤2 yr)
Raw material and resin single-sourcing 0.8 Global Long-term (≥4 yr)

 

Overcapacity Is a Real Risk After 2028

Announced global mammalian capacity expansions point to significant pipeline growth through the late 2020s. Industry demand modelling suggests that utilization could face downward pressure if a substantial portion of this new infrastructure comes online on schedule. Historically, excess capacity and empty suites trigger heightened price competition, leading to noticeable gross margin compression for contract manufacturers when industry utilization dips.

 

Technology Transfer Remains the Failure Point

A notable share of biosimilar tech transfers encounter engineering hurdles because glycosylation profiles can drift outside the required comparability corridor during scale-up. Each repeat campaign involves substantial financial costs and timeline extensions. To mitigate this, sponsors increasingly negotiate accountability clauses into master service agreements, shifting risk onto manufacturers and impacting effective realized pricing.

 

Talent Scarcity Constrains Commissioning

Widespread labor shortages of qualified upstream and downstream process engineers continue to challenge operations across the US and Europe. Consequently, new manufacturing suites frequently experience commissioning delays solely due to staffing constraints and hiring bottlenecks.

 

Biosimilar Contract Manufacturing Market Opportunities

Subcutaneous and High-Concentration Formulations

Originators are converting flagship antibodies to subcutaneous presentations to extend franchise life. Follow-on developers must match those formats, which demand 150–200 mg/mL formulation expertise, viscosity control and specialised device fill lines. Few contract sites offer this today. Manufacturers investing in high-concentration platforms can command 20–30% pricing premiums within the Biosimilar Contract Manufacturing Market.

Emerging-Market Capacity Partnerships

India, Brazil and Saudi Arabia are all funding domestic biologics capability. Brazil's PDP technology-transfer scheme and Saudi Arabia's Vision 2030 localisation targets both offer guaranteed offtake in exchange for in-country manufacture [10][15]. A joint-venture site in Riyadh or Hyderabad captures tender volume that no export model can reach.

Analytics-as-a-Service and Data Monetisation

Comparability packages generate enormous structured datasets. Contract organisations that license anonymised process-analytics benchmarks, predictive glycan-profile models and digital-twin process libraries create recurring revenue independent of bioreactor hours. Several providers now bundle these as premium biosimilar CDMO services priced on subscription rather than per-batch terms.

End-to-End Integrated Programs

Sponsors increasingly prefer one accountable partner from cell-line development through commercial fill-finish. Integrated wins carry contract values three to five times higher than discrete service awards and lock in eight-to-twelve-year relationships, materially raising switching costs across the Biosimilar Contract Manufacturing Market.

Biobetters and Next-Wave Modalities

Antibody-drug conjugates and bispecifics approaching expiry after 2032 need conjugation and dual-chain expression capability. Early investment positions manufacturers for a second growth wave.

 

Biosimilar Contract Manufacturing Market Future Outlook

Digital Twins and Autonomous Bioprocessing

Model-predictive control on perfusion bioreactors is moving from pilot to GMP. Plants running closed-loop nutrient feedback report 11–15% titre gains and materially tighter glycan consistency. By 2032, expect the majority of new suites in the Biosimilar Contract Manufacturing Market to commission with digital-twin validation packages rather than purely empirical process characterisation [20].

Platform Economics and Modality Specialisation

Generalist capacity will commoditise. Winners will specialise — one manufacturer owning high-concentration antibody formulation, another owning microbial peptides, a third owning conjugation chemistry. Specialisation supports 300–500 basis points of gross margin above generalist benchmarks.

Continuous Manufacturing Reaches Commercial Scale

End-to-end continuous processing, connecting perfusion upstream to periodic-counter-current chromatography downstream, eliminates hold steps and shrinks facility footprint by roughly 60%. FDA's Framework for Advanced Manufacturing Technologies designation is accelerating approvals for these lines [21].

Sustainability Becomes a Contract Criterion

Single-use technology cut water and cleaning-chemical consumption sharply but created a plastics burden of roughly 400 tonnes annually per large site. European sponsors now score Scope 3 emissions in vendor selection, and CSRD reporting obligations extend that scrutiny down the supply chain. Carbon intensity per gram is becoming a genuine competitive variable in the Biosimilar Contract Manufacturing Market [22].

 

Biosimilar Contract Manufacturing Market Segmentation

Segment structure across the Biosimilar Contract Manufacturing Market follows the molecular composition of the off-patent pipeline more than any technology preference.

By Production Technology

Segment Metric Primary Demand Driver
Mammalian 74.5% share Antibody and fusion protein dominance
Microbial 25.5% share Insulins, peptides, non-glycosylated proteins

 

Mammalian expression dominates the Biosimilar Contract Manufacturing Market because CHO cells remain the only practical route to human-like glycosylation at scale. Microbial systems retain a durable niche: E. coli produces insulin glargine and filgrastim at a fraction of mammalian cost, and Pichia-based platforms are gaining ground for aglycosylated fragments.

By Product

Segment Metric Primary Demand Driver
Recombinant Glycosylated Proteins USD 6.34 Billion Oncology antibody expiries
Recombinant Non-glycosylated Proteins 38.6% share Insulin and growth factor volume
Recombinant Peptides 15.8% CAGR GLP-1 and teriparatide follow-ons

 

Glycosylated proteins lead the Biosimilar Contract Manufacturing Market on value because comparability demands on glycan profiles make them the most analytically intensive — and therefore highest-priced — programs to manufacture. Peptides grow fastest as semaglutide-class molecules approach expiry in select jurisdictions.

By Application

Segment Metric Primary Demand Driver
Oncology 42.8% share Trastuzumab, bevacizumab, rituximab cohorts
Chronic & Autoimmune Diseases USD 3.09 Billion Anti-TNF and IL-inhibitor expiries
Blood Disorders 12.3% share Epoetin and filgrastim demand
Infectious Diseases 16.4% CAGR Antiviral antibody development
Growth Hormone Deficiency USD 0.71 Billion Somatropin volume in emerging markets
Other Applications 5.4% share Ophthalmology, fertility

 

Oncology holds its lead in the Biosimilar Contract Manufacturing Market largely through checkpoint inhibitors entering the follow-on pipeline. Chronic and autoimmune indications generate steadier volumes, since patients remain on therapy for years and demand forecasting is correspondingly more reliable.

By Service Type

Segment Metric Primary Demand Driver
Upstream Processing 35.2% share Cell-line and bioreactor capacity
Downstream Processing USD 3.72 Billion Purification and chromatography scale
Fill & Finish Operations 16.1% CAGR Prefilled syringe and autoinjector demand
Analytical & QC Studies 12.4% share Comparability and stability testing
Packaging & Labelling USD 0.56 Billion Multi-market serialisation

 

Upstream work commands the largest slice of the Biosimilar Contract Manufacturing Market because it consumes the most capital equipment and the most calendar time. Fill and finish grows fastest as device-integrated presentations replace vials across the biosimilar portfolio.

 

Regional Market Share Analysis

Region Share of Global Revenue (2025) Primary Investment Themes
North America 41.5% Interchangeability filings, onshoring incentives
Europe 27.0% Tender-driven volume, tailored comparability
Asia-Pacific 22.8% Greenfield capacity, cost leadership
South America 5.2% Public procurement, technology transfer
Middle East & Africa 3.5% Localisation mandates, access programs
Total 100.0% —

Regional distribution within the Biosimilar Contract Manufacturing Market reflects where regulatory approval density, capital availability and skilled bioprocess labour intersect.

 

North America

Country Metric Key Driver
US 84.6% of regional revenue FDA interchangeability designations
Canada USD 0.48 Billion pCPA biosimilar switching policies
Mexico 15.7% CAGR COFEPRIS pathway modernisation

 

The United States anchors the Biosimilar Contract Manufacturing Market through sheer approval volume — FDA has licensed more than 65 biosimilars, with 2025 filings running at record pace [1]. CHIPS-style onshoring logic has spread to biologics: the 2024 BIOSECURE legislative push made several large sponsors dual-source away from Chinese sites, redirecting an estimated USD 1.4 billion in annual contract spend toward US and European capacity [11].

Europe

Country Metric Key Driver
Germany 24.8% of regional revenue Dense CDMO cluster, AMNOG pricing
UK USD 0.55 Billion MHRA streamlined biosimilar route
France 14.2% CAGR France 2030 bioproduction fund
Italy 8.1% of regional revenue AIFA regional tender volume
Spain USD 0.24 Billion Andalusian switching programs
Nordic Countries 15.4% CAGR Centralised procurement efficiency
Russia 4.3% of regional revenue Domestic substitution policy
Rest of Europe USD 0.67 Billion CEE cost-competitive capacity

 

Europe's advantage is procurement scale. Danish and Norwegian tenders achieve biosimilar penetration above 90% within twelve months of launch, giving sponsors predictable volume that translates directly into firm capacity reservations [16]. France 2030 has allocated roughly EUR 800 million to bioproduction infrastructure, explicitly targeting the reshoring of essential medicine manufacture [17].

Asia-Pacific

Country Metric Key Driver
China 29.5% of regional revenue NMPA approvals, domestic scale
India USD 0.51 Billion PLI scheme, cost leadership
Japan 14.8% CAGR MHLW biosimilar promotion targets
South Korea 21.2% of regional revenue Songdo mega-capacity cluster
ASEAN USD 0.23 Billion Regional harmonisation efforts
Rest of Asia-Pacific 16.9% CAGR Australia, Taiwan specialist sites

 

Asia-Pacific is where the Biosimilar Contract Manufacturing Market grows fastest, at 17.6% annually. South Korea's Songdo district alone holds over 900,000 litres of installed mammalian capacity, and Samsung Biologics' Plant 5 added 180,000 litres in 2025 [4]. India's Production Linked Incentive scheme for pharmaceuticals has disbursed incentives against roughly USD 2.1 billion of committed biologics investment [18].

South America

Country Metric Key Driver
Brazil 58.2% of regional revenue PDP technology transfer partnerships
Argentina USD 0.14 Billion ANMAT regional export hub role
Rest of South America 15.1% CAGR Colombia, Chile access expansion

 

Brazil's Productive Development Partnership model trades guaranteed Ministry of Health purchasing for local technology transfer, and biosimilar trastuzumab and rituximab have both moved through it [15]. Contract manufacturers willing to accept a decade-long local partner obligation gain access to procurement volumes that bypass conventional tender competition entirely.

Middle East & Africa

Country Metric Key Driver
Saudi Arabia 27.5% of regional revenue Vision 2030 localisation quota
UAE USD 0.09 Billion Free-zone biologics investment
South Africa 16.2% CAGR SAHPRA capacity strengthening
Egypt 12.4% of regional revenue Universal health insurance rollout
Rest of MEA USD 0.08 Billion Gulf cooperative procurement

 

Saudi Arabia's National Unified Procurement Company now applies a local-content preference of up to 20% in bid scoring, which has drawn several international manufacturers into joint ventures near King Abdullah Economic City [19]. Africa's broader picture depends on the African Medicines Agency reaching operational maturity — until then, regulatory fragmentation caps regional scale.

 

Biosimilar Contract Manufacturing Market By Region, 2025-2035

Competitive Benchmarking

Concentration is intense. The estimated HHI is around 1,450, and the top five suppliers account for roughly 52–58% of the global outsourced revenue. The Biosimilar Contract Manufacturing Market rapidly divides into regional specialists and single-modality firms below that tier. Scale advantages are real but not absolute – analytical depth and regulatory track record can trump raw litreage in vendor selection.

Company Est. Revenue Share Range Key Offerings for Biosimilar Contract Manufacturing Market Strategic Positioning
Samsung Biologics ~17–21% Large-scale mammalian, fill-finish, cell-line development Capacity leader; Songdo mega-plant model
Lonza Group ~12–15% Mammalian, microbial, bioconjugation, drug product Broadest modality coverage globally
Boehringer Ingelheim BioXcellence ~7–10% Mammalian, microbial, process characterisation Deep biosimilar regulatory heritage
WuXi Biologics ~6–9% Integrated discovery-to-commercial, perfusion Cost-competitive; navigating geopolitics
Fujifilm Diosynth Biotechnologies ~5–8% Mammalian, microbial, continuous processing Aggressive multi-site expansion
Celltrion ~4–6% Antibody manufacture, in-house biosimilar portfolio Vertically integrated sponsor-manufacturer
Rentschler Biopharma ~3–5% Mammalian, formulation, analytics Mid-scale European specialist
AGC Biologics ~3–4% Mammalian, microbial, plasmid Multi-continent flexible capacity
KBI Biopharma ~2–4% Cell-line development, analytical characterisation Early-phase and comparability strength
Chime Biologics ~2–3% Cell-line, clinical and commercial supply China-based biosimilar specialist
ProBioGen ~1–3% Glycoengineering, cell-line technology Technology licensing plus manufacture
Binex Co., Ltd. ~1–2% Mammalian manufacture, aseptic fill Korean mid-tier provider

 

 

Recent News & Developments

  • Samsung Biologics (April 2025): Completed Plant 5 at Songdo, adding 180,000 litres and lifting total capacity above 780,000 litres — the largest single site globally [4]
  • Lonza (January 2025): Closed acquisition of the Vacaville, California biologics site from Roche for approximately USD 1.2 billion, adding 330,000 litres of US mammalian capacity [5]
  • FDA (June 2025): Issued draft guidance easing switching-study requirements for interchangeable biosimilars, reducing typical development cost by an estimated USD 40–60 million per program [1]
  • Fujifilm Diosynth (October 2024): Opened its Holly Springs, North Carolina facility following a USD 3.2 billion commitment, with eight 20,000-litre bioreactors [6]
  • EMA (March 2024): Published its reflection paper supporting tailored clinical development, signalling that comparative efficacy trials may be waived in defined circumstances [9]
  • Celltrion (September 2024): Announced a USD 1.9 billion multi-year capital plan covering a fourth plant and expanded fill-finish capability [23]
  • Chime Biologics and Kings Pharm (September 2023): Entered a strategic partnership spanning cell-line development, process development and global commercial supply [24]
  • Boehringer Ingelheim (July 2024): Committed EUR 500 million to expand its Biberach biologics site, targeting intensified perfusion trains for follow-on antibodies [25]

 

Biosimilar Contract Manufacturing Market Report Scope

Parameter Detail
Market Scope Global outsourced development and manufacture of biosimilar drug substance and drug product
Study Period 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035)
CAGR 14.9% (2026–2035)
Market Size Checkpoints USD 12.82 Billion (2025); USD 14.73 Billion (2026); USD 51.42 Billion (2035)
Fastest Growing Segments Recombinant Peptides (product); Fill & Finish Operations (service); Asia-Pacific (geography)
Companies Profiled Samsung Biologics, Lonza, Boehringer Ingelheim BioXcellence, WuXi Biologics, Fujifilm Diosynth, Celltrion, Rentschler Biopharma, AGC Biologics, KBI Biopharma, Chime Biologics, ProBioGen, Binex
Valuation Currency USD Billion

FAQs

What contract structures best protect sponsors entering the Biosimilar Contract Manufacturing Market?
Take-or-pay reservations with tiered volume flexibility work best. Sponsors should negotiate comparability-failure remedies and cap batch-failure liability at a defined multiple of batch price [12].
How should a buyer evaluate analytical capability during vendor selection?
Request the vendor's glycan characterisation panel, orthogonal method count and historical comparability success rate. Sites offering fewer than fifteen orthogonal methods rarely survive EMA scrutiny [9].
Does dual-sourcing make sense in the Biosimilar Contract Manufacturing Market?
Yes for commercial-stage products above USD 200 million in projected sales. Second-source qualification costs USD 15–25 million but eliminates single-site regulatory and geopolitical exposure [11].
How do perfusion and fed-batch platforms compare for follow-on antibodies?
Perfusion delivers higher volumetric productivity and a smaller footprint; fed-batch offers simpler validation and broader regulatory precedent. Most sponsors still choose fed-batch for first commercial programs [5].
What regulatory nuance most often delays approval?
Extractables and leachables data from single-use components. Regulators increasingly demand component-specific studies rather than vendor-supplied generic packages [21].
Which emerging use cases will reshape the Biosimilar Contract Manufacturing Market after 2032?
Antibody-drug conjugate and bispecific follow-ons. Both require conjugation suites and dual-chain expression systems that fewer than a dozen sites worldwide currently operate [3].
What integration challenge derails multi-site programs most often?
Data harmonisation across differing manufacturing execution systems. Sponsors who mandate a common electronic batch record schema at contract signature avoid months of reconciliation later [20].      
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Co-Author
Co-Author Profile
Nidhi Mandole LinkedIn
Senior Research Analyst
She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get In Touch
Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample

Research Approach

 

Secondary Research

The secondary research process involved a comprehensive analysis of regulatory databases, peer-reviewed pharmaceutical journals, biopharmaceutical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Generic and Biosimilar Medicines Association (IGBA), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI/PubMed), Institute for Health Metrics and Evaluation (IHME), European Centre for Disease Prevention and Control (ECDC), OECD Health Statistics, and national health ministry reports from key markets including China (NMPA), India (CDSCO), and South Korea (MFDS). These sources were used to collect biosimilar approval data, manufacturing capacity statistics, regulatory pathway analysis, clinical equivalence studies, patent expiration timelines, and market landscape analysis for recombinant glycosylated proteins, recombinant non-glycosylated proteins, mammalian production systems, and non-mammalian bioprocessing technologies.

 

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Manufacturing Operations, Chief Scientific Officers, regulatory affairs leaders, and business development directors from pharmaceutical manufacturers, biotechnology companies, and contract development and manufacturing organizations (CDMOs). The demand-side sources included Chief Medical Officers, head of procurement from biopharmaceutical companies, supply chain directors, and clinical development leaders from the oncology, immunology, and endocrinology therapeutic areas. Primary research has confirmed the timelines for the adoption of manufacturing technologies, validated market segmentation across product types (recombinant glycosylated vs. non-glycosylated proteins), and collected insights on capacity utilization rates, pricing strategies for contract manufacturing services, and partnership dynamics between innovators and CDMOs.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (29%), Asia-Pacific (28%), Rest of World (5%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping and manufacturing capacity analysis. The methodology included:

Identification of 50+ key contract manufacturing organizations across North America, Europe, Asia-Pacific, and Latin America

Product mapping across recombinant glycosylated proteins, recombinant non-glycosylated proteins, and emerging biosimilar categories

Technology segmentation across mammalian cell culture (CHO, NS0, SP2/0) and non-mammalian systems (E. coli, yeast, transgenic)

Analysis of reported and modeled annual revenues specific to biosimilar contract manufacturing portfolios

Coverage of CDMOs representing 75-80% of global biosimilar manufacturing capacity in 2024

Extrapolation using bottom-up (manufacturing capacity × utilization rate × price per liter by region) and top-down (CDMO revenue validation) approaches to derive segment-specific valuations across oncology, blood disorders, growth hormonal deficiency, chronic & autoimmune disorders, and rheumatoid arthritis applications.

Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.